Phyrago Alternatives Compared
| Phyrago (dasatinib) | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|---|
| Phyrago (dasatinib) | Gleevec (imatinib) | Tasigna (nilotinib) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Leukemia. Phyrago may also be used for purposes not listed in this medication guide. |
Prescription only
Gleevec is an oral tyrosine kinase inhibitor that may be used to treat Ph+CML, Ph+ALL, and some other conditions. It may cause fluid retention, nausea, pain, headache, or blood abnormalities and... View more |
Prescription only
Prescribed for Chronic Myelogenous Leukemia. Tasigna may also be used for purposes not listed in this medication guide. |
||||||||||||||||
| More about Phyrago (dasatinib) | More about Gleevec (imatinib) | More about Tasigna (nilotinib) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Be the first to share your experience with this drug. |
Gleevec has an average rating of 8.6 out of 10 from a total of 37 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 5% reported a negative effect. |
Tasigna has an average rating of 7.7 out of 10 from a total of 30 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
|
View all Phyrago side effects |
View all Gleevec side effects |
View all Tasigna side effects |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Gleevec prices |
View all Tasigna prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Other dasatinib brands include: Sprycel | Other imatinib brands include: Imkeldi | Other nilotinib brands include: Danziten | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
5 hours |
40 hours |
17 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 809 drugs are known to interact with Phyrago:
|
A total of 759 drugs are known to interact with Gleevec:
|
A total of 803 drugs are known to interact with Tasigna:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
December 05, 2023 |
May 10, 2001 |
October 29, 2007 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.